This confirmed the rationale for combining therapies: oncolytic vaccinia to increase tumor-infiltrating T cells, dnTGFβmm to reduce TME suppression, and αPD-1 to improve the anti-tumor T cell response and increase intratumoral IFNγ. This evidence concerns the gene IFNG and neoplasm.